Published on August 8, 2008
Exhibit
2.1
CONFIDENTIAL
MATERIAL OMITTED AND
FILED
SEPARATELY WITH THE SECURITIES
AND
EXCHANGE COMMISSION.
ASTERISKS
DENOTE SUCH OMISSIONS.
SECURITIES
PURCHASE AGREEMENT
This
Securities Purchase Agreement is entered into as of May 2, 2008, among VIDUS
OCULAR, INC., a Delaware corporation (the “Company”),
the
individuals and entities listed on Schedule
A
hereto
(individually a “Seller”
and
collectively the “Sellers”),
the
individuals and entities listed on Schedule
B
hereto
(individually a “Noteholder”
and
collectively the “Noteholders”),
OPKO
HEALTH, INC., a Delaware corporation (“OPKO”),
and
OPKO INSTRUMENTATION, LLC, a Delaware limited liability company and wholly-owned
subsidiary of OPKO (“Buyer”).
Preliminary
Statements
A. The
Sellers collectively own all of the outstanding shares of capital stock of
the
Company, and desire to sell to Buyer, and Buyer desires to acquire all of the
capital stock of the Company, on the terms and subject to the conditions set
forth in this Agreement.
B. The
Noteholders collectively hold all of the Notes (as defined in Article 1), and
desire to sell to Buyer, and Buyer desires to acquire all of the Notes and
the
indebtedness represented thereby in exchange for certain shares of OPKO Common
Stock, on the terms and subject to the conditions set forth in this
Agreement.
Agreement
In
consideration of the preliminary statements and the respective mutual covenants,
representations and warranties contained in this Agreement, the parties agree
as
set forth below.
ARTICLE
1
Definitions
In
addition to terms defined elsewhere in this Agreement, the following terms
when
used in this Agreement shall have the meanings indicated below:
“Affiliate”
of
a
specified Person means a Person who directly or indirectly through one or more
intermediaries, controls, or is controlled by, or is under common control with
the specified Person. As used in the foregoing sentence, the term “control”
(including, with correlative meaning, the terms “controlling,” “controlled by”
and “under common control with”) means the possession, directly or indirectly,
of the power to direct or cause the direction of the management and policies
of
such Person, whether through the ownership of voting securities, by contract
or
otherwise, or
such
other relationship as, in fact, constitutes actual control.
“Agreement”
means
this Agreement together with all exhibits and schedules referred to
herein.
“AMEX”
means
the American Stock Exchange, LLC.
“Aquashunt”
means
the Company’s glaucoma drainage device, as improved and modified from time to
time.
“Consideration
Shares”
means,
collectively, the *** Shares, the *** Shares, the True-Up Shares (each as
defined in Section
2.1),
the
Yale Shares and the shares of OPKO Common Stock issued upon exercise of the
Stock Options (as defined in Section
2.1).
“Contracts”
means
all contracts, agreements, covenants, commitments and other instruments of
any
kind, whether oral or written, to which the Company is a party or to which
the
assets or properties of the Company are bound.
“Core
IP Assets”
means
the Yale License and all of the Company’s Intellectual Property as of the
Closing Date (including, without limitation, the Aquashunt), together with
all
preclinical
and clinical studies and data related to the Company’s Intellectual Property
whether or not existing as of the Closing Date.
“Debt”
means
any and all monies owed by the Company to any of the Sellers.
“Environmental
Laws”
means
any Law including any Law relating to pollution or protection of the environment
or natural resources, or the use, handling, transportation, treatment, storage,
disposal, release or discharge of Hazardous Materials.
“ERISA”
means
the Employee Retirement Income Security Act of 1974, as amended.
“Escrow
Agent”
means
Akerman
Senterfitt.
“Escrow
Agreement”
shall
mean that escrow agreement dated the date hereof and substantially in the form
attached hereto as Schedule
C.
“Escrow
Shares”
means
286,624 shares of OPKO Common Stock held in escrow pursuant to the Escrow
Agreement to satisfy Claims under Section 8.5,
as
described on Schedule
D
attached
hereto.
“Exchange
Act”
means
the United States Securities Exchange Act of 1934, as amended, and the rules
and
regulations promulgated thereunder.
“FDA”
means
the United States Food and Drug Administration.
“Founders”
shall
mean Ben R. Bronstein, James R. McNab, Jr., Milton Bruce Shields and Nicholas
Fish Warner.
“GAAP”
means
United States generally accepted accounting principles as in effect on the
date
hereof.
“Guaranty”
means,
as to any Person, any contract, agreement or understanding of such Person
pursuant to which such Person guarantees the indebtedness, liabilities or
obligations of others, directly or indirectly, in any manner, including
agreements to purchase such indebtedness, liabilities or obligations, or to
supply funds to or in any manner invest in others, or to otherwise assure the
holder of such indebtedness, liabilities or obligations against
loss.
2
“Hazardous
Materials”
means
(a) any petroleum, petroleum products, by-products or breakdown products,
radioactive materials, asbestos-containing materials or polychlorinated
byphenyls or (b) any chemical, material or substance defined or regulated as
toxic or hazardous or as a pollutant or contaminant or waste under any
applicable Environmental Law.
“Indemnifying
Noteholder”
means
JM Medical, LLC, a Delaware limited liability company.
“Intellectual
Property”
means
any or all of the following owned, used or controlled by the Company: (a) all
inventions (whether patentable or unpatentable and whether or not reduced to
practice), all improvements thereto, and all patents and patent applications,
together with all reissuances, continuations, continuations-in-part, revisions,
extensions, and reexaminations thereof; (b) all trademarks, service marks,
trade
dress, logos, trade names, and corporate names, together with all translations,
adaptations, derivations, and combinations thereof and including all goodwill
associated therewith, and all applications, registrations, and renewals in
connection therewith; (c) all copyrightable works, all copyrights, and all
applications, registrations, and renewals in connection therewith; (d) all
trade
secrets and confidential business information (including, to the extent such
items are confidential or proprietary to the Company, databases, ideas, research
and development, know-how, formulas, compositions, manufacturing and production
processes and techniques, technical data, designs, drawings, specifications,
customer and supplier lists, pricing and cost information, and business and
marketing plans and proposals); (e) all proprietary computer programs and
software (including data and source and object codes and related documentation);
(f) all other proprietary rights, licenses and sublicenses granted by or to
the
Company that relate to any of the foregoing; and (g) all copies and tangible
embodiments thereof (in whatever form or medium).
“Knowledge”
means
the actual knowledge of the Founders as of the date of this
Agreement.
“Law”
means
any federal, state or local law, statute, ordinance, rule, regulation, order,
writ, judgment or decree.
“Liabilities”
means
any liability (whether known or unknown, whether asserted or unasserted, whether
absolute or contingent, whether accrued or unaccrued, whether liquidated or
unliquidated and whether due or to become due), damages, claims, fines,
penalties, assessments, costs or expenses.
“Liens”
means
any liens, claims, charges, pledges, security interests, mortgages, title
defects or encumbrances.
“Material
Adverse Effect”
means
any change in or effect on the business of a Person that is, or would reasonably
be expected to be, materially adverse to the business, assets (including
intangible assets), liabilities (contingent or otherwise), condition (financial
or otherwise), or results of operations of such Person taken as a whole;
provided, however, that “Material Adverse Effect” shall not include the effect
of any circumstance, change, development, event or state of facts arising out
of
or attributable to any of the following: (a) the industry and markets in which
such Person operates generally, (b) general economic or political conditions,
(c) the failure of such Person to meet projections of earnings, revenues or
other financial measures, including a decline in stock price, in and of itself,
(d) acts of war (whether or not declared), sabotage or terrorism, military
actions or the escalation thereof or other force majeure events (such as natural
disasters, acts of God or other events not within the reasonable control of
such
Person), (e) any changes in applicable Laws or accounting rules, or (f) with
respect to the Company, the taking of any action required by this Agreement
or
consented to by Buyer or OPKO, or, with respect to OPKO, the taking of any
action required by this Agreement or consented to by the Company or the
Sellers.
3
“Notes”
means
those certain 8% convertible promissory notes issued by the Company in favor
of
the Noteholders in the aggregate original principal amount of
$1,275,000.
“OPKO
Affiliate”
shall
mean any Affiliate of OPKO or Buyer, including without limitation, Phillip
Frost, Frost Gamma Investments Trust, The Frost Group, LLC or any of their
respective members or Affiliates.
“OPKO
Common Stock”
means
the common stock of OPKO, par value $.01 per share.
“Organizational
Documents”
means
any and all documents pursuant to which an entity is organized and/or operates
under the applicable laws of its jurisdiction.
“Person”
means
any natural person, corporation, limited liability company, unincorporated
organization, partnership, association, joint stock company, joint venture,
trust or government, or any agency or political subdivision of any government,
or any other entity.
“SEC”
means
the United States Securities and Exchange Commission.
“Securities”
means
all of the issued and outstanding capital stock of the Company.
“Securities
Act”
means
the United States Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.
“Seller
Representative”
shall
mean James R. McNab, Jr.
“Subsidiary”
of
any
Person means any Person, whether or not capitalized, in which such Person owns,
directly or indirectly, an equity interest of 50% or more.
“Tax”
means
any federal, state, local or foreign income, gross receipts, franchise,
estimated, alternative minimum, add-on minimum, sales, use, transfer,
registration, all gross receipts, sales, use, ad
valorem,
value
added, excise, natural resources, severance, stamp, occupation, premium,
windfall profit, assets, minimum income, environmental, customs, duties, real
property, personal property, capital stock, social security obligations or
contributions, unemployment, disability, payroll, license, employee or other
withholding, or other tax or governmental charge, of any kind whatsoever,
including any interest, penalties or additions to tax or additional amounts
in
respect of the foregoing; the foregoing shall include any transferee or
secondary liability for a Tax and any liability assumed by agreement or arising
as a result of being (or ceasing to be) a member of any affiliated group (or
being included, or required to be included, in any tax return relating
thereto).
4
“Transaction
Documents”
means
this Agreement and all other documents to be executed and delivered by any
party
pursuant to or in connection with this Agreement and consummation of the
transactions contemplated hereby.
“Triggering
Event”
means
any of the following events occurring after the Closing: (a) the closing of
the
acquisition of fifty percent (50%) or more of the combined
voting power of the then outstanding voting securities of the Company, Buyer
or
OPKO, as the case may be, entitled to vote generally in the election of
directors or managers (the “Outstanding
Voting Securities”)
of the
Company, Buyer or OPKO, respectively, by any Person (including
a “group” as defined in Section 13(d)(3) of the Securities Exchange Act of
1934, as amended), other
than an OPKO Affiliate; (b) the closing of a merger, conversion or consolidation
of the Company, Buyer or OPKO in which the Company, Buyer, OPKO or an OPKO
Affiliate is not the surviving or resulting entity unless,
following such merger, conversion or consolidation, fifty percent (50%) or
more
of the Outstanding Voting Securities of the surviving or resulting entity is
then beneficially owned, directly or indirectly, by all or substantially all
of
the individuals and entities who were the beneficial owners, respectively,
of
the Outstanding Voting Securities immediately prior to such merger, conversion
or consolidation of the Company, Buyer or OPKO, as applicable; (c) the closing
of a sale, transfer or other disposition of all or substantially all of the
assets of the Company, Buyer or OPKO to any Person other than an OPKO Affiliate
(including
a “group” as defined in Section 13(d)(3) of the Securities Exchange Act of
1934, as amended);
or (d)
the closing of a sale or transfer (including an exclusive license or sub-license
to all or substantially all of the Intellectual Property relating to the
Aquashunt, including, without limitation, an exclusive license or any sublicense
of the Yale License) to any Person other than an OPKO Affiliate or the Founders
in accordance with Section 8.1(b) of all or substantially all of the properties,
assets or rights related to the Aquashunt.
“Yale”
means
Yale University, a corporation organized and existing under and by virtue of
a
charter granted by the general assembly of the Colony and State of
Connecticut.
“Yale
License”
means
that certain Exclusive License Agreement effective as of February 13, 2007
by
and between Yale and the Company.
“Yale
Shares”
means
33,080 shares of OPKO Common Stock.
ARTICLE
2
Purchase
of Securities; Purchase of Notes; Release by Escrow Agent
2.1 Purchase
of Securities.
(a) Purchase
and Sale of Securities.
Subject
to the terms and conditions set forth herein, on the Closing Date, each Seller
shall sell, assign, transfer and deliver to Buyer, and Buyer shall purchase
from
such Seller, all of such Seller’s right, title and interest in and to the
Securities indicated next to such Seller’s name on Schedule
A
under
the heading “Securities
Owned”.
To give
effect to such sale, each of the Sellers hereby waives any preemption rights
it
may have in relation to any of the Securities.
5
(b) Consideration.
As
consideration for the sale, assignment, transfer and delivery of the Securities
by the Sellers to Buyer, Buyer shall issue and deliver to the Sellers (or the
Escrow Agent on behalf of the Sellers, as applicable), on the terms and
conditions set forth herein, the following number of shares of OPKO Common
Stock
and options to acquire shares of OPKO Common Stock:
(i) On
or
before the Closing Date, OPKO’s Board of Directors (or compensation committee
thereof) shall grant to each Founder and, on the Closing Date, Buyer shall
issue
and deliver to each Founder, stock options representing the right to acquire
50,000 shares of OPKO Common Stock, at an exercise price equal to the closing
sale price for OPKO Common Stock on the AMEX on the Closing Date
(the
“Stock
Options”).
Each
Founder’s Stock Options shall (i) have the terms set forth in Schedule
E
(“Option
Terms”),
(ii)
be for a term of seven (7) years, (iii) vest ratably over four (4) years vest,
and (iv) be governed by the terms and conditions of OPKO’s 2007 Equity Incentive
Plan (the “OPKO
Stock Option Plan”)
as in
effect on the Closing Date (including, without limitation, with respect to
accelerated vesting upon a Change in Control (as such term is defined in the
OPKO Stock Option Plan), provided,
however,
that
the Stock Options shall become fully vested and exercisable immediately upon
the
occurrence of a Triggering Event. For the avoidance of doubt, notwithstanding
anything to the contrary in this Agreement, the Stock Options or the OPKO Stock
Option Plan, vesting of the Stock Options shall be subject only to the passage
of time and shall not be contingent upon service by the Founders as employees
or
consultants of the Company, Buyer or OPKO under any circumstances.
(ii) On
the
Closing Date, Buyer shall issue and deliver a certificate to Yale representing
24,810 shares of OPKO Common Stock (or 75% of the Yale Shares), and issue to
Yale, and deliver to the Escrow Agent to be held in escrow pursuant to the
terms
of this Agreement and the Escrow Agreement, a certificate representing 8,270
shares of OPKO Common Stock (or 25% of the Yale Shares).
(iii) On
the
Closing Date, Buyer shall issue certificates to each Seller representing the
number of shares of OPKO Common Stock set forth opposite the name of such Seller
on Schedule
A
under
the heading “***
Shares”
(the
“***
Shares”),
and
deliver such certificates to the Escrow Agent to be held in escrow pursuant
to
the terms of this Agreement and the Escrow Agreement.
(iv) On
the
Closing Date, Buyer shall issue certificates to each Seller representing the
number of shares of OPKO Common Stock set forth opposite the name of such Seller
on Schedule
A
under
the heading “***
Shares”
(the
“***
Shares”),
and
deliver such certificates to the Escrow Agent to be held in escrow pursuant
to
the terms of this Agreement and the Escrow Agreement.
(c) Additional
Consideration.
In the
event the average closing sale price for OPKO Common Stock on the AMEX for
the
ten (10) trading days preceding the date of the 510(k) Approval is less than
$*** per share, then Buyer shall issue and deliver (as soon as possible and
in
any event within *** business days of the date of the 510(k) Approval) to each
Seller a certificate representing the number of shares of OPKO Common Stock
set
forth opposite the name of such Seller on Schedule
A
under
the heading “True-Up
Shares”
(the
“True-Up
Shares”).
6
2.2 Purchase
of Notes.
(a) Purchase
and Sale of Notes.
Subject
to the terms and conditions set forth herein, on the Closing Date, each
Noteholder shall sell, assign, transfer and deliver to Buyer, and Buyer shall
purchase from such Noteholder, all of such Noteholder’s right, title and
interest in and to the Note(s) including the aggregate indebtedness represented
thereby (including the aggregate original principal amount thereof and the
accrued and unpaid interest thereon) indicated next to such Noteholder’s name on
Schedule
B.
(b) Consideration.
As
consideration for the sale, assignment, transfer and delivery of the Notes,
on
the Closing Date, Buyer shall (i) issue and deliver to each Noteholder a
certificate representing the number of shares of OPKO Common Stock set forth
opposite the name of such Noteholder on Schedule
B
under
the heading “Note
Shares”
(the
“Note
Shares”);
and
(ii) issue to the Indemnifying Noteholder a certificate representing the number
of shares of OPKO Common Stock set forth opposite the name of the Indemnifying
Noteholder on Schedule
B
under
the heading “Note
Indemnity Shares”
(the
“Note
Indemnity Shares”),
and
deliver such certificate to the Escrow Agent to be held in escrow pursuant
to
the terms of this Agreement and the Escrow Agreement; following which each
of
the Notes shall be deemed fully repaid, canceled and of no further
effect.
2.3 Release
By Escrow Agent.
(a) Release
of *** Shares.
Subject
to Section
2.3(c)
and
Section
2.3(d),
Buyer
and the Seller Representative shall direct the Escrow Agent to immediately
release the *** Shares, other than the *** shares constituting part of the
Escrow Shares, to the Sellers immediately after the earlier to occur of (i)
***,
as determined by OPKO in its sole discretion, of *** (defined in Section
8.1(a)),
and
(ii) a ***. Unless a *** has occurred, Buyer and the Seller Representative
shall
direct the Escrow Agent to immediately release the *** Shares to Buyer in the
event that OPKO determines in its sole discretion that the *** in accordance
with Section
8.1(a)
hereof.
(b) Release
of ***
Shares.
Subject
to Section
2.3(c)
and
Section
2.3(d),
Buyer
and the Seller Representative shall direct the Escrow Agent to immediately
release the *** Shares, other than the *** Shares constituting part of the
Escrow Shares, to the Sellers immediately after the earliest to occur of (i)
***, and ***. Unless
a
*** has occurred, Buyer and the Seller Representative shall direct the Escrow
Agent to immediately release the *** Shares to Buyer in the event *** (defined
in Section
8.1(a)).
(c) Escrow
Shares.
Subject
to Section
2.3(a),
Section
2.3(b)
and
Section
2.3(d),
Buyer
and the Seller Representative shall direct the Escrow Agent to immediately
release the Escrow Shares to the Sellers and the Indemnifying Noteholder on
the
earlier of (i) the *** anniversary of the Closing Date, unless a Claim asserted
in writing by a Buyer Indemnified Party remains unresolved as of such date,
and
(ii) ***.
7
(d) ***
Escrow
Shares.
Notwithstanding anything in Section
2.3(a),
Section
2.3(b),
or
Section
2.3(c)
to the
contrary, none of the ***
Shares
or
***
Shares
constituting part of the Escrow Shares shall be released or delivered to the
Sellers, if ever, until the ***
(i)
***,
as
determined by Buyer in its sole discretion, of ***, ***,
respectively, and (ii) the occurrence of a ***.
ARTICLE
3
Representations
and Warranties of Buyer and OPKO
In
order
to induce the Company and Sellers to enter into this Agreement and to consummate
the transactions contemplated hereby, Buyer and OPKO make the representations
and warranties set forth below to Sellers.
3.1 Organization.
Each of
Buyer and OPKO has been duly organized and is validly existing and in good
standing under the laws of the jurisdiction of its incorporation or
organization, as the case may be. Each of Buyer and OPKO is duly qualified
or
licensed to do business, and is in good standing, in each jurisdiction where
the
character of the properties owned, leased or operated by it or the nature of
its
business makes such qualification or licensing necessary. Each of Buyer and
OPKO
has all requisite right, power and authority to (a) own or lease and operate
its
properties and (b) conduct its business as presently conducted.
3.2 Authorization;
Enforceability.
Each
of
Buyer and OPKO has all requisite right, power and authority to execute and
deliver the Transaction Documents and to consummate the transactions
contemplated thereby. The execution and delivery of the Transaction Documents
by
Buyer and OPKO and the consummation by Buyer and OPKO of the transactions
contemplated thereby have been duly authorized by all requisite corporate and
limited liability company action, as the case may be. The Transaction Documents
have been duly executed and delivered by Buyer and OPKO, and constitute the
legal, valid and binding obligation of Buyer and OPKO, enforceable in accordance
with their respective terms except as limited by (a) applicable bankruptcy,
insolvency, reorganization, moratorium or other Laws of general application
affecting enforcement of creditors’ rights and (b) general principles of equity
that may restrict the availability of equitable remedies.
3.3 No
Violation or Conflict.
The
execution and delivery of the Transaction Documents by Buyer and OPKO, the
consummation by Buyer and OPKO of the transactions contemplated thereby, and
compliance by Buyer and OPKO with the provisions hereof: (a) do not and will
not
violate or, if applicable, conflict with any provision of Law, or any provision
of Buyer’s or OPKO’s Organizational Documents; and (b) do not and will not, with
or without the passage of time or the giving of notice, result in the breach
of,
or constitute a default, cause the acceleration of performance or require any
consent under, any instrument or agreement to which Buyer or OPKO is a party
or
by which Buyer, OPKO or their properties may be bound or affected.
3.4 Capitalization. The
authorized and outstanding capital stock of OPKO is as set forth on its
consolidated balance sheet comprising a part of the most recent SEC Report.
All
of OPKO’s issued and outstanding capital stock is duly authorized, validly
issued, fully paid and nonassessable and was issued in compliance with
applicable state and federal securities laws. As of the date hereof, there
are
outstanding options to purchase approximately 12,300,000 shares of OPKO Common
Stock under the OPKO Stock Option Plan, and options to purchase 18,300,000
shares of OPKO Common Stock remain available for grant thereunder.
8
3.5 Validity
of Shares; Listing.
When
issued and delivered to the Sellers and the Noteholders in accordance with
this
Agreement, the Note Shares, the Note Indemnity Shares and the Consideration
Shares shall be (a) duly and validly authorized, issued and outstanding, (b)
fully paid and nonassessable, and (c) listed for trading on the
AMEX.
3.6 SEC
Reports; Absence of Undisclosed Liabilities.
(a) Except
as
set forth on Schedule
3.6(a),
OPKO
has duly filed with and furnished to the SEC all required reports, schedules,
forms, certifications, prospectuses, registrations, proxy and other statements
since March 27, 2007 (collectively, “SEC
Reports”).
Each
SEC Report complied, at the time such SEC Report was filed, in all material
respects with all applicable requirements of the Securities Act and the Exchange
Act and applicable rules and regulations promulgated thereunder.
(b) Neither
OPKO nor any of its subsidiaries has any Liabilities which, if known, would
be
required to be reflected or reserved against on a consolidated balance sheet
of
OPKO prepared in accordance with GAAP or the notes thereto, except Liabilities
(i) reflected or reserved against on the audited consolidated balance sheet
of OPKO and its subsidiaries as of December 31, 2007 and the footnotes thereto
set forth in OPKO’s annual report on Form 10-K, for the fiscal year ended
December 31, 2007, or (ii) incurred after December 31, 2007 in the ordinary
course of business and that, individually or in the aggregate, have not had
a
Material Adverse Effect.
3.7 Absence
of Certain Changes or Events.
Except
as disclosed in the SEC Reports, (a) since December 31, 2007, there has not
occurred any Material Adverse Effect, and (b) OPKO and its subsidiaries
have carried on and operated their respective businesses in all material
respects in the ordinary course of business consistent with past
practices.
3.8 Legal
Proceedings.
Except
as set forth in the SEC Reports, (a) OPKO is not a party to any pending or,
to
the knowledge of OPKO, threatened, legal, administrative or other proceeding,
arbitration, mediation or out-of-court settlement negotiation, and (b) to the
knowledge of OPKO, no Person who is or was a director or officer of OPKO is
a
party to any pending legal, administrative or other proceeding, arbitration,
mediation or out-of-court settlement negotiation in their capacity as directors
or officers of OPKO. OPKO is not subject to any order, writ, injunction, decree
or other judgment of any court or governmental or regulatory
authority.
3.9 Compliance
with Laws.
Except
as discussed in the SEC Reports, OPKO is in compliance in all material respects
with all Laws and other legal requirements applicable to it or its properties
and OPKO has not received written notification from any governmental or
regulatory authority asserting that it is not in compliance with or has violated
any of the Laws, which such governmental or regulatory authority enforces,
or
threatening to revoke any Permit (as hereinafter defined), and OPKO is not
subject to any agreement or consent decree with any governmental or regulatory
authority arising out of previously asserted violations.
9
3.10 Consent
of Governmental Authorities.
No
consent, approval or authorization of, or registration, qualification or filing
with any governmental or regulatory authority is required to be made by OPKO
in
connection with the execution, delivery or performance of this Agreement by
OPKO
or the consummation by OPKO of the transactions contemplated
hereby.
3.11 Brokers.
Buyer
has not employed any financial advisor, broker or finder and has not incurred
and will not incur any broker’s, finder’s, investment banking or similar fees,
commissions or expenses, in connection with the transactions contemplated by
this Agreement, which would be payable by Sellers.
ARTICLE
4
Representations
and Warranties of the Company
In
order
to induce Buyer and OPKO to enter into this Agreement and to consummate the
transactions contemplated hereby, the Company hereby makes the representations
and warranties set forth below to Buyer and OPKO, which are subject to the
qualifications and limitations set forth in the disclosure schedules attached
hereto (the “Disclosure
Schedules”).
4.1 Organization.
The
Company has been duly organized and is validly existing and in good standing
under the laws of the jurisdiction of its incorporation. The Company is duly
qualified or licensed to do business, and is in good standing, in each
jurisdiction where the character of the properties owned, leased or operated
by
it or the nature of its business makes such qualification or licensing
necessary. The Company has all requisite right, power and authority to (a)
own
or lease and operate its properties, (b) conduct its business as presently
conducted and (c) engage in and consummate the transactions contemplated hereby.
The Company is not in default under its Organizational Documents. The Company
does not have any Subsidiaries.
4.2 Authorization;
Enforceability.
The
Company has all requisite right, power and authority to execute and deliver
the
Transaction Documents and consummate the transactions contemplated thereby.
The
execution and delivery of the Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby have been duly
authorized by all requisite corporate action. The Transaction Documents have
been duly executed and delivered and constitute the legal, valid and binding
obligations of the Company, enforceable in accordance with their respective
terms except as limited by (a) applicable bankruptcy, insolvency,
reorganization, moratorium or other Laws of general application affecting
enforcement of creditors’ rights and (b) general principles of equity that may
restrict the availability of equitable remedies.
4.3 No
Violation or Conflict.
Except
as set forth on Schedule
4.3,
the
execution and delivery of the Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby, and
compliance by the Company with the provisions hereof: (a) do not and will not
violate or conflict with any provision of Law or any provision of the Company’s
Organizational Documents; and (b) do not and will not, with or without the
passage of time or the giving of notice, result in the breach of, or constitute
a default, cause the acceleration of performance or require any consent under,
or result in the creation of any Lien upon any property or assets of the Company
pursuant to any instrument or agreement to which the Company is a party or
by
which the Company’s properties may be bound or affected.
10
4.4 Organizational
Documents and Corporate Records.
A true
and complete copy of (a) the Organizational Documents of the Company, as
amended, and (b) copies of the minute books of the Company have been delivered
to Buyer. Such minute books contain records of all meetings and other corporate
actions of the Board of Directors, committees of the Board of Directors, and
shareholders of the Company from the date of its incorporation to the date
hereof, and such records are complete and accurate in all material respects.
All
matters requiring the authorization or approval of the Board of Directors,
a
committee of the Board of Directors, or the shareholders of the Company have
been duly and validly authorized and approved by them.
4.5 Capitalization.
The
authorized share capital of the Company is as set forth on Schedule
4.5.
Schedule
4.5
sets
forth all Securities which are issued and outstanding, all of which have been
duly authorized, are validly issued, fully paid and nonassessable and were
issued in compliance with applicable state and federal securities laws. All
outstanding Securities are owned by the Sellers, free and clear of all Liens,
rights of first refusal and limitations on the Sellers’ voting rights, and there
are no voting agreements or shareholder agreements among the Sellers with
respect to the Securities. The Company has not made any investment or equity
interest in any other Person. None of the Securities was issued in violation
of
any preemptive rights or rights of first refusal, or other agreements or rights.
At the Closing, the Sellers will transfer and convey and Buyer will acquire
good
and valid title to the Securities free and clear of all Liens. No written or
oral agreement or understanding with respect to the disposition of the
Securities or any rights therein, other than this Agreement exists. The Company
does not have any liability or obligation of any nature whatsoever to any former
shareholder of the Company.
4.6 Rights,
Warrants, Options.
There
are no stock options, warrants, stock appreciation, phantom stock or other
rights, arrangements or commitments of any character to which the Company is
a
party or by which the Company is bound relating to the issued or unissued
capital stock or equity interests of the Company or obligating the Company
to
issue or sell any shares of capital stock of, or other equity interests in,
the
Company. There are no outstanding obligations of the Company to redeem or
otherwise acquire any of the Securities. There are no outstanding contractual
obligations of the Company to provide funds to, or make any investment (in
the
form of a loan, capital contribution or otherwise) in any Person.
4.7 Financial
Statements.
The
Company has delivered to Buyer a true and complete copy of (A) the unaudited
consolidated balance sheet of the Company for the fiscal year ended on December
31, 2007, and the unaudited consolidated profit and loss statement for the
fiscal year ended on December 31, 2007, and (B) the unaudited balance sheet
of
the Company as of March 31, 2008, and the unaudited consolidated profit and
loss
statement of the Company for the two-month period then ended (collectively,
the
“Financial
Statements”).
The
Financial Statements: (a) have been prepared in accordance with the books of
account and records of the Company; (b) fairly present in all material respects
the financial position of the Company as of the dates and for the periods
specified in such statements; and (c) have been prepared in accordance with
United States generally accepted accounting principles, consistently applied
with prior periods, subject to year-end adjustments and the addition of
appropriate footnotes.
11
4.8 Absence
of Undisclosed Liabilities.
The
Company has no debts, Liabilities, commitments or obligations of any nature
whatsoever, whether accrued, absolute, contingent or otherwise, other than
as
provided for in this Agreement, disclosed in the Disclosure Schedules or accrued
for or reserved against in the Financial Statements.
4.9 Guaranties.
The
Company is not a party to any Guaranty, and no Person is a party to any Guaranty
for the benefit of the Company.
4.10 Accounts
and Notes Receivable and Payable.
Set
forth in Schedule
4.10
is a
true and complete aged list of unpaid accounts and notes receivable owing to
and
owed by the Company as of Closing. All of such accounts and notes receivable
and
payable constitute only bona fide, valid and binding claims arising in the
ordinary course of the Company’s business, subject, with regard to receivables,
to no valid defenses, counterclaims or setoffs.
4.11 Absence
of Material Adverse Effect.
Except
as set forth on Schedule
4.11,
Since
March 31, 2008, the Company has conducted its business only in the ordinary
and
usual course and in a manner consistent with past practices and, since such
date: (a) there has been no Material Adverse Effect; and (b) the Company has
not
engaged or agreed to engage in any of the actions described below:
(a) amend
or
otherwise change its Organizational Documents;
(b) issue,
sell or authorize for issuance or sale, shares of any class of its securities
(including, but not limited to, by way of stock split or dividend) or any
subscriptions, options, warrants, rights or convertible securities, or enter
into any agreements or commitments of any character obligating it issue or
sell
any such securities;
(c) redeem,
purchase or otherwise acquire, directly or indirectly, any shares of its capital
stock or any option, warrant or other right to purchase or acquire any such
shares;
(d) declare
or pay any dividend or other distribution (whether in cash, stock or other
property) with respect to its capital stock or repay any irrevocable capital
contribution;
(e) sell,
transfer, surrender, abandon or dispose of any of its assets or property rights
(tangible or intangible);
(f) grant
or
make any Lien or subject itself or any of its properties or assets to any Lien;
(g) grant
any
license or sublicense of any right under or with respect to any Intellectual
Property or disclose any proprietary or confidential information to any third
party, except to Buyer or OPKO;
(h) create,
incur or assume any indebtedness or any Liability in excess of
$7,500;
(i) make
or
commit to make any capital expenditures in excess of $7,500;
(j) grant
or
become subject to any Guaranty;
12
(k) apply
any
of its assets to the direct or indirect payment, discharge, satisfaction or
reduction of any amount payable directly or indirectly by, to or for the benefit
of any Seller or any Affiliate thereof or to the prepayment of any such amounts
or engage in any transactions with any Affiliate;
(l) write
off
the value of any assets, inventory or any accounts receivable or increase,
the
reserves for obsolete, damaged, spoiled or otherwise not usable inventory or
doubtful or uncollectible receivables;
(m) increase
the compensation payable or to become payable to directors, officers or
employees (including, without limitation, any such increase pursuant to any
Plan
or otherwise), other than increases in the ordinary course of business and
consistent with past practice or grant any rights to severance or termination
pay to, or enter into any employment or severance agreement with, any director,
officer or other employee of the Company, or establish, adopt, enter into or
materially amend any collective bargaining, bonus, profit sharing, thrift,
compensation, stock option, restricted stock, pension, retirement, deferred
compensation, employment, termination, severance or other plan, agreement,
trust, fund, policy or arrangement for the benefit of any director, officer
or
employee;
(n) acquire
(including, without limitation, by merger, consolidation or acquisition of
stock
or assets) any interest in any corporation, partnership, other business
organization, Person or any division thereof or any assets;
(o) alter
the
manner of keeping its books, accounts or records, or change in any manner the
accounting practices, methods or assumptions therein reflected;
(p) agree
to
accelerate or delay collection of notes or accounts receivable in advance of
or
beyond their regular dates or the date when the same could have been collected
in the ordinary course of business consistent with past practices;
(q) waive,
release, assign, settle or compromise any claims or litigation;
(r) make
any
Tax election or settle or compromise any federal, state or local or federal
income Tax liability;
(s) take
or
omit to take any action which is intended to render any of the Company’s
representations or warranties untrue or misleading;
(t) take
any
action which would have a Material Adverse Effect; or
(u) agree,
whether in writing or otherwise, to do any of the foregoing.
4.12 List
of Accounts.
Set
forth on Schedule
4.12
is: (a)
the name and address of each bank or other institution in which the Company
maintains an account (cash, securities or other) or safe deposit box; (b) the
name and phone number of the Company’s contact person at such bank or
institution; (c) the account number of the relevant account and a description
of
the type of account; and (d) the persons authorized to transact business in
such
accounts.
13
4.13 Tax
Matters.
Except
as set forth on Schedule
4.13,
all Tax
returns required to be filed with respect to the Company have been timely filed
with the appropriate governmental authorities in all jurisdictions in which
such
returns are required to be filed, all of the foregoing as filed are true,
correct and complete in all material respects as of the applicable filing dates,
and reflect accurately in all material respects all liabilities for Taxes of
the
Company for the periods to which such returns relate, and all amounts shown
as
owing thereon have been paid. All Taxes, if any, collectible or payable by
the
Company or relating to or chargeable against any of its assets, revenues or
income through the Closing Date were or will be fully collected and paid by
such
date or provided for by adequate reserves in the Financial Statements. No claims
or deficiencies have been asserted against the Company with respect to any
Taxes
which have not been paid or otherwise satisfied or for which accruals or
reserves have not been made in the Financial Statements, and there exists no
reasonable basis for the making of any such claims. The Company has not waived
any restrictions on assessment or collection of Taxes or consented to the
extension of any statute of limitations relating to taxation.
4.14 Insurance.
Set
forth on Schedule
4.14
is a
list of all insurance policies providing insurance coverage of any nature to
the
Company. The Company has delivered to Buyer a true and complete copy of all
of
such insurance policies as amended. Such policies are reasonably sufficient
for
the compliance by the Company with all requirements of Law and all Contracts.
All of such policies are in full force and effect and are valid and enforceable
in accordance with their terms, and the Company has complied in all material
respects with all terms and conditions of such policies, including the payment
of premium payments. None of the insurance carriers has indicated to the Company
an intention to cancel or not renew any such policy. The Company has no claim
pending or reasonably anticipated against any of the insurance carriers under
any of such policies and there has been no actual or alleged occurrence of
any
kind which may give rise to any such claim.
4.15 Title
to and Condition of Personal Property.
(a) Except
as
set forth on Schedule
4.15,
the
Company has good and marketable title or leasehold interest to each item of
equipment and other personal property, included as an asset in the Financial
Statements, free and clear of all Liens.
(b) All
of
the buildings, structures, appurtenances, leasehold improvements, equipment,
machinery, and other tangible property owned or used by the Company are: (a)
in
reasonable operating condition and repair, ordinary wear and tear excepted,
(b)
not in need of substantial maintenance or repairs, and (c) adequate and
sufficient for the continuing conduct of the business of the Company as now
conducted.
(c) Each
item
of equipment, personal property and asset of the Company, included as an asset
in the Financial Statements shall remain with the Company as of the Closing
Date. The parties agree that Schedule
4.15(c)
sets
forth the full and complete list of material assets which will be owned by
the
Company as of the Closing Date.
14
4.16 Intellectual
Property.
Other
than inbound “shrink-wrap” and similar publicly available commercial binary code
end-user licenses, set forth on Schedule
4.16
is a
list and description of the Intellectual Property that is the subject of an
application, certificate, filing, registration or other document issued by,
filed with, or recorded by, any governmental authority. The Intellectual
Property is owned or rightfully used by the Company pursuant to a license
agreement free and clear of all Liens, and except as set forth on Schedule
4.16,
no
royalties, honorariums or fees are or will be payable by the Company by reason
of the ownership or use of the Intellectual Property. No claims have been made
against the Company or the Sellers or, to the Knowledge of the Company,
threatened against the Company or the Sellers (or any of their respective
officers, directors, employees or Affiliates) (i) asserting the invalidity,
abuse, misuse, or unenforceability, or seeking the cancellation, of any of
the
Intellectual Property, or (ii) asserting that the Company’s ownership or use of
the Intellectual Property infringes or violates the rights of any other Person
and, to the Company’s Knowledge, there does not exist any valid basis for any
such claim. To the Knowledge of the Company, there is no infringement or
misappropriation of any Intellectual Property. The Intellectual Property
includes all rights necessary for the Company to be legally entitled to conduct
its business as presently being conducted. Subject to obtaining such consents
set forth in Schedule
4.16,
the
consummation of the transactions contemplated hereby will not alter or impair
any of the Intellectual Property. Except as set forth in
Schedule 4.16,
no
interest in any of the Intellectual Property has been assigned, transferred,
licensed or sublicensed by the Company to third parties.
4.17 Real
Property.
The
Company does not own any real property. Schedule
4.17
sets
forth the street address of each parcel of real property leased by the Company
(the “Leased
Property”).
The
Company has delivered to Buyer true and complete copies of all of the lease
agreements, as amended to date (the “Leases”)
relating to the Leased Property. Except as set forth in Schedule
4.17,
(i) no
Person other than the Company has any right to use or occupy any part of the
Leased Property, and (ii) the Company has no Knowledge that any Lease will
not
be renewed by the landlord upon its expiration date on terms and conditions
substantially similar to the terms existing thereunder, if requested to do
so by
the Company. The Company has not made an construction or improvements on the
Leased Property.
4.18 Compliance
with Environmental Laws.
The
Company is in compliance in all material respects with all applicable
Environmental Laws. There have been no governmental claims, citations, notices
of violation, judgments, decrees or orders issued against the Company for
impairment or damage, injury or adverse effect to the environment or public
health and, to the Knowledge of the Company there have been no private
complaints with respect to any such matters. To the Knowledge of the Company,
there is no condition relating to any properties of the Company that would
require any type of remediation, clean-up, response or other action under
applicable Environmental Laws. The Company has complied in all material respects
with all applicable Environmental Laws in the generation, treatment,
transportation, storage and disposal of Hazardous Materials.
4.19 Employment
Matters.
15
(a) Employment
Agreements.
Except
as listed on Schedule
4.19(a),
there
are no (i) employment agreements, (ii) consulting agreements, (iii) severance
agreements, (iv) agreements that include indemnification arrangements, or (v)
agreements which contain change of control provisions, between the Company
and
any officer, director, consultant or employee (“Employment
Agreements”).
Sellers have delivered to Buyer true and complete copies of all of the
Employment Agreements. No Employment Agreement (i) will require any payment
by
the Company or Buyer to any director, officer or employee of the Company, or
any
other party, by reason of the change in control of the Company resulting from
the transactions contemplated by this Agreement, or (ii) provides for the
acceleration or change in the award, grant, vesting or determination of options,
warrants, rights, severance payments, or other contingent obligations of any
nature whatsoever of the Company in favor of any such parties. The terms of
employment or engagement of all directors, officers, employees, agents,
consultants and professional advisers of the Company are such that their
employment or engagement may be terminated at any time without liability for
payment of compensation or damages (other than, with respect to employees of
the
Company, the payment of the statutory minimum compensation) and the Company
has
not entered into any agreement or arrangement for the management of its business
or any part thereof other than with its directors or employees.
(b) Personnel.
Schedule
4.19(b)
contains
the names, job descriptions and annual salary rates and other compensation
of
any kind of all officers, directors and consultants of the Company (including
compensation paid or payable by the Company under the Plans (as hereafter
defined)).
(c) Employment
Laws.
The
Company has complied in all material respects with all applicable employment
Laws, including payroll, withholding and related obligations, benefits, social
security, and does not have any obligation in respect of any amount due to
employees of the Company or government agencies, other than normal salary,
other
fringe benefits and contributions accrued but not payable on the date
hereof.
(d) Policies.
Schedule
4.19(d)
contains
a list of all employee policies (written or otherwise), employee manuals or
other written statements of rules or policies concerning employment, including
working conditions, vacation and sick leave, a complete copy of each of which
(or a description, if unwritten) has been delivered to Buyer.
(e) Employee
Benefit Plans.
(i) Except
as
set forth in Schedule
4.19,
the
Company does not and has never maintained and has no material liability with
respect to (A) any employee pension benefit plan as defined in Section 3(2)A
of
ERISA, or (B) any other deferred compensation, stock purchase, stock bonus,
stock ownership, stock option, profit sharing, savings, medical, disability,
hospitalization, insurance, deferred compensation, bonus, incentive, welfare
or
any other employee benefit plan, policy, agreement, commitment, arrangement
or
practice currently or previously maintained by the Company for any of its
directors, officers, consultants, employees or former employees (collectively,
“Plans”).
The
Company has delivered to Buyer a true and complete copy of all of the Plans
or,
if oral, an accurate written summary thereof.
(ii) Schedule
4.19(e)
contains
a list setting forth each employee welfare benefit plan as defined in Section
3(1) of ERISA adopted by the Company (each, a “Welfare
Plan”).
Except as may be required by applicable Law, the Company is not obligated under
any Welfare Plan to provide medical or death benefits with respect to any
employee or former employee of the Company or its predecessors after termination
of employment. The Company has complied with the notice and continuation
coverage requirements of Section 4980B of the Internal Revenue Code of 1986,
as
amended (the “Code”)
and
the regulations thereunder with respect to each Welfare Plan that is a group
health plan within the meaning of Section 5000(b)(1) of the Code. There are
no
reserves, assets, surplus or prepaid premiums under any Welfare
Plan.
16
(iii) Each
Plan
and Welfare Plan has been administered in accordance with its terms and
applicable Law. With respect to the Plans, (A) no event has occurred and there
exists no condition, facts or circumstances which would reasonably be expected
to give rise to any Liability of the Company under the terms of such Plans
or
any Law governing such Plans (other than Liabilities for benefits under such
Plans in the ordinary course), (B) the Company has paid or accrued in accordance
with its normal accounting practices all amounts required under applicable
Law
and any Plan to be paid as a contribution to each Plan through the date hereof,
(C) the Company has set aside adequate reserves to meet contributions which
are
not yet due under any Plan, (D) the fair market value of the assets of each
funded Plan, the liability of each insurer for any Plan funded through insurance
or the book reserve established for any Plan, together with accrued
contributions, is sufficient to procure or provide for the accrued benefit
obligations, as of the Closing Date, with respect to all current and former
participants in such Plan according to the actuarial assumptions and valuations
most recently used to determine employee contributions to such Plan and no
transaction contemplated by this Agreement shall cause such assets or insurance
obligations to be less than such benefit obligations, and (E) each Plan required
to be registered has been registered and has been maintained in good standing
with applicable regulatory authorities.
(iv) On
or
after the date hereof, no Plan has been, or will be, (A) terminated, (B) amended
in any manner which would directly or indirectly increase the benefits accrued,
or which may be accrued, by any participant thereunder or (C) amended in any
manner which would materially increase the cost to the Company or Buyer of
maintaining such Plan. Except as set forth in Schedule 4.19(e), there are no
material amounts due or owing to any employee of the Company for any accrued
salary, remuneration, compensation and/or benefit, including, without
limitation, amounts due for accrued vacation, sick leave or
commissions.
4.20 Labor
Relations.
There
is no strike or dispute pending or, to the Knowledge of the Company, threatened,
involving the Company and any employees of the Company. To the Knowledge of
the
Company, none of the employees of the Company is a member of any labor union,
and the Company is not a party to or otherwise bound by any labor or collective
bargaining agreement. To the Knowledge of the Company, none of the employees
of
the Company is engaged in organizing any labor union or other employee group
that is seeking recognition as a bargaining unit. There are no unfair labor
practice complaints pending or, to the Knowledge of the Company, threatened,
against the Company, and no Person has made any claim, and there is no basis
for
any claim, against the Company under any statute, regulation or ordinance
relating to employees or employment practices, including without limitation
those relating to age, sex and racial discrimination, conditions of employment,
and wages and hours.
4.21 Contracts.
Schedule
4.21
sets
forth a list of all Contracts (other than those which are terminable upon no
more than 30 days notice by the Company without penalty or other adverse
consequence), including, without limitation:
17
(a) each
partnership, joint venture or similar agreement of the Company with another
Person;
(b) each
contract or agreement under which the Company has created, incurred, assumed
or
guaranteed (or may create, incur, assume or guarantee) indebtedness in any
amount or under which the Company has imposed (or may impose) a Lien on any
of
their respective assets, whether tangible or intangible securing
indebtedness;
(c) each
contract or agreement which involves an aggregate payment or commitment per
contract or agreement on the part of the Company of more than US $5,000 per
year;
(d) all
leases and subleases from any third person to the Company, in each case
requiring annual lease payments in excess of US $5,000;
(e) each
contract or agreement to which the Company or any of its Affiliates is a party
limiting the right of the Company or any of its Affiliates (i) to engage in,
or
to compete with any person in, any business, including each contract or
agreement containing exclusivity provisions restricting the geographical area
in
which, or the method by which, any business may be conducted by the Company
or
any of its Affiliates or (ii) to solicit any customer or client;
(f) all
licenses, licensing agreements and other agreements providing in whole or part
for the use of any Intellectual Property by any third party; and
(g) each
contract or agreement which contain anti-assignment, change of control or notice
of assignment provisions.
Schedule
4.21
further
identifies each Contract which would require that the Company give notice to,
or
obtain the consent of, another party to such Contract as a result of
transactions contemplated by this Agreement. The Contracts are each in full
force and effect and are the valid and legally binding obligations of the
Company and, to the Company’s Knowledge, are valid and binding obligations of
the other parties thereto (in each case, except as limited by (a) applicable
bankruptcy, insolvency, reorganization, moratorium or other Laws of general
application affecting enforcement of creditors’ rights and (b) general
principles of equity that may restrict the availability of equitable remedies).
The Company has not received written notice of default by the Company under
any
of the Contracts, and the Company is not in default under any Contract, and
no
event has occurred which with the giving of notice or lapse of time or both
would constitute such a default. The Company has previously delivered or will
deliver prior to the Closing Date to Buyer true, complete and correct copies
of
all contracts listed on Schedule
4.21.
None
of
the Contracts was entered into outside the ordinary course of business of the
Company and none contains any provisions that would reasonably be expected
to
impair or adversely affect in any material way the operations of the Company,
or
would reasonably be expected to be performed at a material loss.
4.22 Related
Parties.
To the
Knowledge of the Company, no current officer or director of the Company (a)
owns, directly or indirectly, any interest in, or is a director, officer,
employee, consultant or agent of, any Person which is a competitor of the
Company; (b) owns, directly or indirectly, in whole or in part, any property,
asset or right, real, personal or mixed, tangible or intangible, including
any
Intellectual Property, used in the conduct of the Company’s business; (c) has an
interest in or is, directly or indirectly, a party to any Contract; or (d)
has
any cause of action or claim whatsoever against, or is indebted to the Company
on account of borrowed money.
18
4.23 Absence
of Certain Business Practices.
Neither
the Company, nor, to the Knowledge of the Company, any of the Sellers or the
current directors, officers, employees or consultants of the Company, acting
alone or together, has: (a) received, directly or indirectly, any unlawful
rebates, payments, commissions, promotional allowances or any other economic
benefits, regardless of their nature or type, from any customer, supplier,
employee or agent of any customer or supplier, official or employee of any
government (domestic or foreign) or other Person; or (b) directly or indirectly,
given or agreed to give any unlawful money, gift or similar benefit to any
customer, supplier, employee or agent of any customer or supplier, official
or
employee of any government (domestic or foreign), or any political party or
candidate for office (domestic or foreign) or other Person who was, is or may
be
in a position to help or hinder the business of the Company (or assist the
Company in connection with any actual or proposed transaction).
4.24 Compliance
with Laws.
The
Company is in compliance in all material respects with all Laws and other legal
requirements applicable to it or its properties. The Company has not received
written notification from any governmental or regulatory authority asserting
that it is not in compliance with or has violated any of the Laws, which such
governmental or regulatory authority enforces, or threatening to revoke any
Permit (as hereinafter defined), and the Company is not subject to any agreement
or consent decree with any governmental or regulatory authority arising out
of
previously asserted violations.
4.25 Governmental
Authorizations.
The
Company has all authorizations, consents, approvals, franchises, licenses and
permits required under applicable Law for the ownership of the Company’s
properties and operation of its business as presently operated (the
“Permits”).
No
suspension nonrenewal or cancellation of any of the Permits is pending or,
to
the Knowledge of the Company, threatened, and there is no reasonable basis
therefor. The Company is not, in any material respect, in conflict with, or
in
default or violation of any material Permits.
4.26 Legal
Proceedings.
Except
as set forth in Schedule
4.26,
(a) the
Company is not a party to any pending or, to the Knowledge of the Company,
threatened, legal, administrative or other proceeding, arbitration, mediation
or
out-of-court settlement negotiation, and (b) to the Knowledge of the Company,
no
Person who is or was a director or officer of the Company is a party to any
pending or threatened legal, administrative or other proceeding, arbitration,
mediation or out-of-court settlement negotiation in their capacity as directors
or officers of the Company. The Company is not subject to any order, writ,
injunction, decree or other judgment of any court or governmental or regulatory
authority.
4.27 Assets and
Rights.
The
assets and rights owned by the Company constitute all assets and rights required
to operate
the
business of the Company as presently conducted.
4.28 Consent
of Governmental Authorities.
No
consent, approval or authorization of, or registration, qualification or filing
with any governmental or regulatory authority is required to be made by the
Company in connection with the execution, delivery or performance of this
Agreement by the Company or the consummation by the Company of the transactions
contemplated hereby.
19
4.29 Brokers.
Except
as set forth in Schedule
4.29,
the
Company has not employed any financial advisor, broker or finder and has not
incurred and will not incur any broker’s, finder’s, investment banking or
similar fees, commissions or expenses in connection with the transactions
contemplated by this Agreement, which would be payable by the Company or
Buyer.
4.30 Disclaimer.
Except
for the representations and warranties contained in this Article 4 and any
other
agreement contemplated by this Agreement or delivered in connection with the
transactions hereunder, the Company makes no other representations or
warranties, express or implied, and the Company hereby disclaims any such other
representations or warranties, whether by the Company or any of its officers,
directors, employees, agents or representatives or any other Person with respect
to this Agreement and the transactions contemplated hereby, notwithstanding
the
delivery or disclosure to Buyer or OPKO or any of their respective officers,
directors, employees, agents or representatives or any other Person, of any
documentation or other information by the Company or any of its officers,
directors, employees, agents or representatives or any other Person, with
respect to any of the foregoing.
ARTICLE
5
Representations
and Warranties of The Sellers
In
order
to induce Buyer and OPKO to enter into this Agreement and to consummate the
transactions contemplated hereby, each Seller, severally and not jointly, hereby
makes the representations and warranties set forth below to Buyer and OPKO
with
respect to himself or itself (provided that Yale shall not be deemed to make
the
representations and warranties in either Section
5.5
or
Section
5.8).
5.1 Title
to Securities.
Such
Seller is the record and beneficial owner of the Securities listed opposite
its
name on Schedule
A
(the
“Seller’s
Shares”),
and
the Seller’s Shares are owned free and clear of any Liens whatsoever, including,
without limitation, claims or rights under any voting trust agreements,
shareholder agreements or other agreements. At the Closing, such Seller will
transfer and convey, and Buyer will acquire, good and valid title to the
Seller’s Shares, free and clear of all Liens whatsoever.
5.2 Authorization;
Enforceability.
Such
Seller has all requisite right, power and authority to execute and deliver
the
Transaction Documents and to consummate the transactions contemplated thereby.
Such Seller has all requisite right, power and authority to transfer the
Seller’s Shares. The Transaction Documents have been duly executed and delivered
by such Seller and constitute the legal, valid and binding obligations of such
Seller, enforceable in accordance with their respective terms, except as limited
by (a) applicable bankruptcy, insolvency, reorganization, moratorium or other
Laws of general application affecting enforcement of creditors’ rights and (b)
general principles of equity that may restrict the availability of equitable
remedies.
20
5.3 No
Consent, Violation or Conflict.
With
respect to such Seller, the execution and delivery of the Transaction Documents
by such Seller and the consummation by such Seller of the transactions
contemplated hereby, and compliance by the Seller with the provisions hereof,
(a) do not require any prior governmental or regulatory consent, approval,
or
notice of any kind, (b) do not and will not violate or, if applicable, conflict
with any provision of Law, and (c) do not and will not, with or without the
passage of time or the giving of notice, result in the breach of, or constitute
a default, cause the acceleration of performance or require any consent under,
or result in the creation of any Lien upon any property or assets of such Seller
pursuant to any instrument or agreement to which such Seller is a party or
by
which such Seller or such Seller’s properties may be bound or
affected.
5.4 Litigation.
There
are no suits or proceedings pending or, to the knowledge of such Seller,
threatened, before any court or by or before any governmental or regulatory
authority, commission, bureau or agency or public regulatory body against such
Seller which, if adversely determined, would interfere with Seller’s ability to
consummate the transactions contemplated hereby.
5.5 Related
Parties.
Such
Seller does not own, directly or indirectly, any significant interest in, or
is
a director, officer, employee, consultant or agent of, any Person which is
a
competitor of the Company; (b) owns, directly or indirectly, in whole or in
part, any property, asset or right, real, personal or mixed, tangible or
intangible that is material to the business, financial condition, prospects
or
results of operations of the Company taken as a whole; or (c) has an interest
in
or is, directly or indirectly, a party to any Contract (other than as an
employee, consultant or lender to the Company).
5.6 Investment
Intent; Securities Documents.
Such
Seller understands and acknowledges that the Consideration Shares are being
offered for exchange in reliance upon the exemption provided in Section 4(2)
of
the Securities Act for nonpublic offerings. Such Seller represents that it
is
acquiring the Consideration Shares hereunder for its own account, for investment
and not with a view to, or for the sale in connection with, any distribution
of
any of the Consideration Shares, except in compliance with applicable state
and
federal securities laws. Such Seller has had the opportunity to obtain such
information pertaining to Buyer and OPKO as has been requested, including but
not limited to filings made by OPKO with the SEC under the Exchange Act. Such
Seller represents that it is an “accredited investor” within the meaning of
Regulation D promulgated under the Securities Act, and has such knowledge and
experience in business or financial matters that it is capable of evaluating
the
merits and risks of an investment in the Consideration Shares.
5.7 Restrictions
on Resale.
Such
Seller understands and acknowledges that the Consideration Shares have not
been
registered with the SEC under the Securities Act and the certificates
representing the Consideration Shares shall bear an appropriate restrictive
legend. Such Seller further understands and acknowledges that any sale, transfer
or disposition by them of any of the Consideration Shares may, under current
law, be made only in
accordance with Rule 144 of the Securities Act or another exception to the
Securities Act.
21
5.8 Company
Representations and Warranties.
Such
Seller has read the representations and warranties of the Company set forth
in
Article 4 and, to the actual knowledge of such Seller as of the date of this
Agreement (without any inquiry or investigation or duty of inquiry or
investigation), each of the Company Representations, as qualified by the
Disclosure Schedules, is true and correct in all material respects as of the
date of this Agreement.
ARTICLE
6
Representations
and Warranties of The Noteholders
In
order
to induce Buyer and OPKO to enter into this Agreement and to consummate the
transactions contemplated hereby, each Noteholder, severally and not jointly,
hereby makes the representations and warranties set forth below to Buyer and
OPKO with respect to himself, herself or itself.
6.1 Title
to Notes.
Such
Noteholder is the record and beneficial owner of the Note(s) listed opposite
its
name on Schedule
B
(the
“Noteholder’s
Notes”),
and
the Noteholder’s Notes are owned free and clear of any Liens whatsoever,
including, without limitation, claims or rights under any voting trust
agreements, shareholder agreements or other agreements. At the Closing, such
Noteholder will transfer and convey, and Buyer will acquire, good and valid
title to the Noteholder’s Notes, free and clear of all Liens
whatsoever.
6.2 Authorization;
Enforceability.
Such
Noteholder has all requisite right, power and authority to execute and deliver
the Transaction Documents and to consummate the transactions contemplated
thereby. Such Noteholder has all requisite right, power and authority to
transfer the Noteholder’s Notes. The Transaction Documents have been duly
executed and delivered by such Noteholder and constitute the legal, valid and
binding obligations of such Noteholder, enforceable in accordance with their
respective terms, except as limited by (a) applicable bankruptcy, insolvency,
reorganization, moratorium or other Laws of general application affecting
enforcement of creditors’ rights and (b) general principles of equity that may
restrict the availability of equitable remedies.
6.3 No
Consent, Violation or Conflict.
With
respect to such Noteholder, the execution and delivery of the Transaction
Documents by such Noteholder and the consummation by such Noteholder of the
transactions contemplated hereby, and compliance by such Noteholder with the
provisions hereof, (a) do not require any prior governmental or regulatory
consent, approval, or notice of any kind, (b) do not and will not violate or,
if
applicable, conflict with any provision of Law, or any provision of such
Noteholder’s Organizational Documents, and (c) do not and will not, with or
without the passage of time or the giving of notice, result in the breach of,
or
constitute a default, cause the acceleration of performance or require any
consent under, or result in the creation of any Lien upon any property or assets
of such Noteholder pursuant to any instrument or agreement to which such
Noteholder is a party or by which such Noteholder or such Noteholder’s
properties may be bound or affected.
6.4 Litigation.
There
are no suits or proceedings pending or, to the knowledge of such Noteholder,
threatened, before any court or by or before any governmental or regulatory
authority, commission, bureau or agency or public regulatory body against
Noteholders which, if adversely determined, would interfere with Noteholders’
ability to consummate the transactions contemplated hereby.
22
6.5 Related
Parties.
Such
Noteholder does not own, directly or indirectly, any significant interest in,
or
is a director, officer, employee, consultant or agent of, any Person which
is a
competitor of the Company; (b) owns, directly or indirectly, in whole or in
part, any property, asset or right, real, personal or mixed, tangible or
intangible that is material to the business, financial condition, prospects
or
results of operations of the Company taken as a whole; or (c) has an interest
in
or is, directly or indirectly, a party to any Contract (other than as an
employee, consultant or lender to the Company).
6.6 Investment
Intent; Securities Documents.
Such
Noteholder understands and acknowledges that the Note Shares are being offered
for exchange in reliance upon the exemption provided in Section 4(2) of the
Securities Act for nonpublic offerings. Such Noteholder represents that it
is
acquiring the Note Shares hereunder for its own account, for investment and
not
with a view to, or for the sale in connection with, any distribution of any
of
the Note Shares, except in compliance with applicable state and federal
securities laws. Such Noteholder has had the opportunity to obtain such
information pertaining to Buyer and OPKO as has been requested, including but
not limited to filings made by OPKO with the SEC under the Exchange Act. Such
Noteholder represents that it is an “accredited investor” within the meaning of
Regulation D promulgated under the Securities Act, and has such knowledge and
experience in business or financial matters that it is capable of evaluating
the
merits and risks of an investment in the Note Shares.
6.7 Restrictions
on Resale.
Such
Noteholder understands and acknowledges that the Note Shares and the Note
Indemnity Shares have not been registered with the SEC under the Securities
Act
and the certificates representing the Note Shares and the Note Indemnity Shares
shall bear an appropriate restrictive legend. Such Noteholder further
understands and acknowledges that any sale, transfer or disposition by them
of
any of the Notes Shares or the Note Indemnity Shares may, under current law,
be
made only in
accordance with Rule 144 of the Securities Act or another exception to the
Securities Act.
ARTICLE
7
Closing;
Closing Deliverables
7.1 Closing.
The
closing of the transactions contemplated by, and the transfers and deliveries
to
be made pursuant to, this Agreement (the “Closing”)
shall
take place by electronic exchange of signature pages simultaneously with the
execution of this Agreement (the “Closing
Date”).
All
proceedings to be taken and all documents to be executed at the Closing shall
be
deemed to have been taken, delivered and executed simultaneously, and no
proceeding shall be deemed taken nor documents deemed executed or delivered
until all have been taken, delivered and executed.
23
7.2 OPKO
Deliverables.
At or
before the Closing, OPKO shall deliver or cause to be delivered:
(a) to
the
Company and the Seller’s Representative:
(i) a
true
and complete copy, certified by the Secretary or Assistant Secretary of OPKO,
of
the resolutions duly and validly adopted unanimously by the Board of Directors
of OPKO evidencing its authorization of the execution and delivery of the
Transaction Documents and the consummation of the transactions contemplated
thereby;
(ii) a
certificate of OPKO, executed by a duly authorized officer of OPKO, that (i)
the
representations and warranties of OPKO contained in this Agreement are
true
and
correct in all material respects (except for those representations and
warranties which are by their terms qualified by materiality or Material Adverse
Effect, which shall be true and correct in all respects, and except to the
extent such representations and warranties are as of another date, in which
case
as of such date), and (ii) the
covenants
and agreements of OPKO contained in this Agreement to be performed or complied
with on or prior to the Closing Date shall have been duly performed or complied
with in all material respects;
(iii) all
filings, consents, approvals, permits and authorizations required to be obtained
by OPKO in connection with this Agreement or the transactions contemplated
thereby;
(iv) such
other documents and instruments as the Company or the Seller’s Representative
may reasonably request (other than opinions of counsel); and
(b) to
the
Escrow Agent:
(i) an
executed counterpart of the Escrow Agreement; and
(ii) certificates
representing the ***
Shares,
the ***
Shares,
the Note Indemnity Shares and 25% of the Yale Shares;
(c) to
the
Noteholders:
(i) certificates
representing the Note Shares;
(d) to
Yale:
(i) a
certificate representing 24,810 shares of OPKO Common Stock;
(e) to
the
Founders:
(i) a
grant
of Stock Options having the Option Terms described herein;
(f) to
Ben R.
Bronstein:
(i) an
offer
letter for employment with Buyer post-Closing in the form attached hereto as
Schedule
F-1;
24
(g) to
Milton
B. Shields:
(i) an
amendment to his current Consulting Agreement with the Company providing for
a
consulting engagement with Buyer post-Closing in the form attached hereto as
Schedule
F-2;
and
(h) to
Nicholas F. Warner:
(i) an
offer
letter for employment with Buyer post-Closing in the form attached hereto as
Schedule
F-3.
7.3 Company
Deliverables.
At or
before the Closing, the Company shall deliver or cause to be delivered to
Buyer:
(a) a
true
and complete copy, certified by the Secretary or Assistant Secretary of the
Company, of the resolutions duly and validly adopted unanimously by the Board
of
Directors of the Company evidencing its authorization of the execution and
delivery of the Transaction Documents and the consummation of the transactions
contemplated thereby;
(b) a
certificate of the Company, executed by a duly authorized officer of the
Company, that (i) the representations and warranties of the Company contained
in
this Agreement are true
and
correct in all material respects (except for those representations and
warranties which are by their terms qualified by materiality or Material Adverse
Effect, which shall be true and correct in all respects, and except to the
extent such representations and warranties are as of another date, in which
case
as of such date), and (ii) the
covenants
and agreements of the Company contained in this Agreement to be performed or
complied with on or prior to the Closing Date shall have been duly performed
or
complied with in all material respects;
(c) all
filings, consents, approvals, permits and authorizations to be obtained by
the
Company which
Buyer reasonably deems necessary to consummate the transactions contemplated
by
this Agreement, each in form and substance reasonably satisfactory to Buyer
and
without the imposition of any material adverse terms or conditions which would
materially adversely affect Buyer or its ability to operate the Company after
the Closing;
(d) the
effective written resignations of each of the directors and officers of the
Company and the Founders (as employees or consultants), as may be requested
by
Buyer; and
(e) such
other documents and instruments as Buyer may reasonably request (other than
opinions of counsel).
7.4 Seller
Deliverables.
At or
before the Closing, each Seller shall deliver or cause to be delivered to Buyer
(a) certificates issued by the Company evidencing the ownership of the Seller’s
Shares; and (b) such other documents and instruments as Buyer may reasonably
request (other than opinions of counsel).
25
7.5 Noteholder
Deliverables.
At or
before the Closing, each Noteholder shall deliver or cause to be delivered
to
Buyer (a) the Noteholder’s Notes; and (b) such other documents and instruments
as Buyer may reasonably request (other than opinions of counsel).
ARTICLE
8
Additional
Agreements
8.1 OPKO
Covenants and Commitments; Transfer of Core IP Assets.
(a) As
additional consideration for the sale of the Securities pursuant to this
Agreement, OPKO agrees (i) to use commercially reasonable efforts to
***,
(ii) to
use commercially reasonable efforts to complete the same on or before
***
(the
“***
Completion Date”),
and
(iii) to use commercially reasonable efforts to ***,
provided that each of the ***
Date
and
the ***
Date
shall be extended ***
Representative
in the event OPKO determines in good faith it is unable to meet either deadline
despite utilizing commercially reasonable efforts. OPKO shall make a
determination, in its sole discretion, ***
after
the
***
Completion
Date, as amended (the “Determination
Date”)
and
immediately notify the Seller Representative of the same.
(b) In
the
event that (i) ***
on
or
before the ***
(as
extended, if applicable), (ii) OPKO determines, in its sole discretion,
***.
In the
event of a ***,
each of
the Founders acknowledges and agrees that all unexercised Stock Options
***,
and the
Founders shall each represent and warrant, among other things, as to their
ability to consummate the ***,
***,
and
that such shares ***,
will be
***.
OPKO,
Buyer and the Company shall represent and warrant as to their ability to
consummate the ***
and
that
***.
Upon
***,
(i)
OPKO, Buyer and the Company, and (ii) the Founders (or their designee), shall
execute mutual general releases in favor of the other. For
the
avoidance of doubt, (A) nothing in this Agreement shall operate to amend, modify
or waive any of the terms of the Yale License as in effect on the date hereof,
and (B) nothing in this Agreement shall operate or be interpreted as a consent
by Yale to any assignment or purported assignment (or any license or sub-license
to the rights and licenses granted thereunder) by the Company, Buyer or OPKO
after the Closing.
8.2 Investigation.
The
representations, warranties and covenants set forth in this Agreement shall
not
be affected or diminished in any way by any investigation (or failure to
investigate) at any time by or on behalf of the party for whose benefit such
representations, warranties and covenants were made.
8.3 Survival
of the Representations and Warranties.
The
representations and warranties of Buyer, OPKO, the Sellers, the Noteholders
and
the Company set forth in this Agreement shall survive the Closing Date for
a
period of one year.
8.4 General
Release.
(a) As
additional consideration for the sale of the Securities pursuant to this
Agreement, each of the Sellers and the Noteholders hereby unconditionally and
irrevocably releases and forever discharges, effective as of the Closing Date,
each of the Company and its officers, directors, employees and agents (each,
a
“Seller
Releasee”),
from
any and all rights, claims, demands, judgments, obligations, liabilities and
damages, whether accrued or unaccrued, asserted or unasserted, and whether
known
or unknown, relating to the Company which ever existed, now exist, or may
hereafter exist, by reason of any tort, breach of contract, violation of law
or
other act or failure to act which shall have occurred at or prior to the Closing
Date, but excluding claims for breach by a Seller Releasee of any provision
of
this Agreement or any document or agreement executed and/or delivered pursuant
hereto. Except as provided in the preceding sentence, the Sellers and the
Noteholders expressly intend that the foregoing release shall be effective
regardless of whether the basis for any claim or right hereby released shall
have been known to or anticipated by the Sellers.
26
(b) As
additional consideration for the sale of the Securities pursuant to this
Agreement, each of the Company, Buyer and OPKO hereby unconditionally and
irrevocably releases and forever discharges, effective as of the Closing Date,
each of the Sellers and the Noteholders and their respective officers,
directors, employees and agents, as applicable (each, a “Released
Party”),
from
any and all rights, claims, demands, judgments, obligations, liabilities and
damages, whether accrued or unaccrued, asserted or unasserted, and whether
known
or unknown, which ever existed, now exist, or may hereafter exist, by reason
of
any tort, breach of contract, violation of law or other act or failure to act
which shall have occurred at or prior to the Closing Date, but excluding claims
(i) for breach by a Released Party of any provision of this Agreement or any
document or agreement executed and/or delivered pursuant hereto, (ii) for fraud,
misappropriation, or willful misconduct, or (iii) in connection with or relating
to any derivative action brought by any Seller or a former stockholder of the
Company. Except as provided in the preceding sentence, the Company, Buyer and
OPKO expressly intend that the foregoing release shall be effective regardless
of whether the basis for any claim or right hereby released shall have been
known to or anticipated by the Company, Buyer or OPKO.
8.5 Indemnification.
(a) Indemnification
from the Escrow Shares.
Subject
in all cases to the limitations set forth in Section
8.5(d),
Section
8.5(e)
and
Section
8.5(f),
the
Sellers and the Indemnifying
Noteholder
agree,
severally and not jointly up to their respective Pro Rata Share (as defined
in
Section 8.5(f)), to indemnify and hold harmless, Buyer and OPKO and their
respective directors, officers, employees and agents (collectively,
“Buyer
Indemnified Parties”)
from,
against and in respect of, each of the following (collectively, “Claims”):
(i) (A)
any
and all Liabilities, arising from, in connection with, or incident to any breach
or violation of any of the representations and warranties of any of the Sellers,
the Noteholders or the Company contained in this Agreement or any certificate
delivered by any of the Sellers at or prior to the Closing, or (B) any and
all
Liabilities arising from, in connection with, or incident to any breach or
violation of the covenants or agreements of any of the Sellers, the Noteholders
or the Company contained in this Agreement,
(ii) any
and
all Liabilities for Taxes attributable to all Tax years or portions thereof
ending on or prior to the Closing Date imposed with respect to the
Company,
27
(iii) any
and
all Taxes related to or arising from the transactions contemplated hereby or
in
contemplation hereof by reason of any Liability for Taxes of the Company or
the
Sellers and assessed by any taxing authority against the Sellers, their
respective shareholders, the Company and/or any of their respective Affiliates
either before or after the Closing Date,
(iv) any
and
all actions, suits, proceedings, demands, assessments or judgments, costs and
expenses incidental to any of the foregoing, and
(v) any
third
party claim, action, suit or proceeding or of the occurrence of any event or
the
existence of any state of facts which may become the basis of a third party
claim
(b) Indemnification
Procedure.
(i) As
soon
as practicable after Buyer obtains knowledge of the existence or commencement
of
any Claim in respect of which a Buyer Indemnified Party is entitled to
indemnification under this Agreement, Buyer shall notify the Seller
Representative and the Escrow Agent of such Claim in writing; provided,
however,
that
any failure to give notice (A) will not waive any rights of the Buyer
Indemnified Parties and (B) will not relieve the Sellers of their obligations
as
hereinafter provided in this Section
8.5
after
such notice is given, except to the extent that the Seller Representative shall
have been materially adversely affected by such delay or failure and except
that
in any event such notice shall be given on or before the one year anniversary
of
the Closing Date. Such notice shall specify the amount of the Claim (or the
Buyer Indemnified Party’s good faith estimate of the amount of the Claim if the
amount is not yet determined) and a reasonably detailed summary of the basis
for
such Claim.
(ii) If
the
Seller Representative does not dispute the basis or amount of any Claim within
30 days of receiving written notice thereof, Buyer shall have the right to
promptly recover indemnity as and to the extent provided herein, and the Seller
Representative and Buyer shall provide a Joint Written Direction (as defined
in
the Escrow Agreement) to the Escrow Agent containing instructions to that
effect. If the Seller Representative disagrees with the basis of the Claim
or
the amount of damages caused or alleged to be caused thereby, then within 30
days of receiving written notice thereof, the Seller Representative shall give
notice to Buyer and the Escrow Agent of such disagreement and, in that case,
Buyer shall have no right to recover indemnity hereunder until such time, if
at
all, as (A) a court of competent jurisdiction issues a final, non-appealable
order specifying the amount of Buyer’s recovery or (B) Buyer and the Seller
Representative agree in writing to the amount of recovery.
(iii) With
respect to any Claim under Section
8.5(a)(v)
as to
which such notice is promptly given, the Seller Representative will assume
the
defense or otherwise settle such Claim with counsel reasonably satisfactory
to
Buyer experienced in the conduct of Claims of that nature at the Sellers’ and
the Indemnifying Noteholder’s sole risk and expense; provided, however, that
Buyer (A) shall be permitted to join the defense and settlement of such Claim
and to employ counsel reasonably satisfactory to it at its expense, and (B)
shall cooperate fully with the Seller Representative, the Sellers and the and
the Indemnifying Noteholder in the defense and any settlement of such Claim
in
any manner reasonably requested by the Seller Representative. The Seller
Representative shall not make any settlement of any claims without the written
consent of Buyer, which consent shall not be unreasonably withheld or delayed.
Without limiting the generality of the foregoing, it shall not be deemed
unreasonable to withhold consent to any third party claim, action, suit or
proceeding or of the occurrence of any event or the existence of any state
of
facts which may become the basis of a third party claim a settlement involving
injunctive or other equitable relief against Buyer or its Affiliates or their
assets, employees or business. For purposes of this Section, the firm of Foley
Hoag LLP
is
satisfactory to Buyer and any conflict of interest of any form as to Foley
Hoag
LLP
is
hereby waived to the extent permitted by law.
28
(iv) If
the
Seller Representative fails to assume the defense of such Claim or, having
assumed the defense and settlement of such Claim, fails reasonably to contest
such Claim in good faith, or the remedy sought by the claimant with respect
to
such Claim is not solely for money damages, Buyer, without waiving its right
to
indemnification, may, but is not required to, assume the defense and settlement
of such Claim at the Sellers’ expense, provided, however, that (A) the Sellers
shall cooperate with Buyer in the defense and settlement of such Claim in any
manner reasonably requested by Buyer, and (B) Buyer shall not settle such Claim
without the written consent of the Sellers and the Indemnifying Noteholder,
which consent shall not be unreasonably withheld or delayed.
(c) Indemnification
Payments Net of Taxes.
All
sums payable by the Sellers and the Indemnifying Noteholder as indemnification
under this Section
8.5
shall be
paid free and clear of all deductions or withholdings (including any Taxes
or
governmental charges of any nature) unless the deduction or withholding is
required by law, in which event or in the event Buyer shall incur any liability
for Tax chargeable or assessable in respect of any such payment, the Sellers
and
the Indemnifying Noteholder shall pay such additional amounts as shall be
required to cause the net amount received by Buyer to equal the full amount
which would otherwise have been received by it had no such deduction or
withholding been made or no such liability for Taxes been incurred.
(d) Limitation
on Indemnification.
Satisfaction of Claims, other than with respect to Claims for fraud, shall
be
subject to the following limitations:
(i) the
Buyer
Indemnified Parties shall not be entitled to any indemnification under this
Agreement for Claims ***;
provided that after the Buyer Minimum Loss Limitation has been met, the Buyer
Indemnified Parties shall be entitled to indemnification for all damages, costs
and expenses, relating to Claims going back to the first dollar;
(ii) the
Buyer
Indemnified Parties shall not be entitled to any indemnification under this
Agreement for any loss of use, interruption of business, special, punitive,
consequential or incidental damages or loss of profit or goodwill;
and
(iii) the
amount of any indemnification under this Agreement payable hereunder with
respect to any Claim shall be reduced by the proceeds of any insurance policy
paid to any Buyer Indemnified Party with respect to such Claim.
(e) Escrow
Shares.
The
Escrow Shares shall be the sole and exclusive source of recovery by the Buyer
Indemnified Parties on account of any Claim for indemnification under this
Section
8.5.
Subject
to the provisions of Section 8.5(f), recovery on account of an undisputed or
otherwise resolved Claim for indemnification shall be made by set-off against
the Escrow Shares by releasing from escrow and delivering to Buyer (in trust
for
the applicable Buyer Indemnified Party), in accordance with the terms of the
Escrow Agreement, that number of shares of OPKO Common Stock equal to the dollar
amount of the Claim, divided by the price per share of OPKO Common Stock which
shall be valued at ***
for
OPKO
Common Stock on the AMEX on the ***.
29
(f) Pro
Rata Share.
Any
set-off against the Escrow Shares in satisfaction of an undisputed or otherwise
resolved Claim for indemnification pursuant to this Agreement shall be made
on a
pro rata basis among the Sellers and the Indemnifying Noteholder, calculated
by
dividing (i) the number of Escrow Shares indicated
next to such Seller’s
or Indemnifying Noteholder’s name
on
Schedule
D
under
the heading “Escrow
Shares” ,
by (ii)
the total number of Escrow Shares (each Seller’s and the Indemnifying
Noteholder’s respective “Pro
Rata Share”);
provided,
however,
that
(A) any Claim arising from, in connection with, or incident to any breach or
violation of any of the representations and warranties of a Seller contained
in
Article 5 shall be made by set-off only against such Seller’s Escrow Shares, and
(B) any Claim arising from, in connection with, or incident to any breach or
violation of any of the representations and warranties of any of the Noteholders
contained in Article 6 shall be made by set-off only against the Indemnifying
Noteholder’s Escrow Shares.
(g) Exclusive
Remedy.
Other
than with respect to Claims for fraud, the indemnification provided in this
Section
8.5
will be
the exclusive remedy for the Buyer Indemnified Parties with respect to Claims
against the Sellers, the Noteholders, the Seller Representative or the Company
with respect to any provision of this Agreement and the transactions
contemplated hereby.
(h) Binding
Effect.
Buyer
shall administer the requirements and provisions of this Agreement including
the
defense and/or settlement of any Claims for which the Buyer Indemnified Parties
may be indemnified. All decisions and actions by Buyer, including the defense
or
settlement of any Claims for which the Buyer Indemnified Parties may be
indemnified, shall be binding upon all of the Buyer Indemnified Parties, and
no
Buyer Indemnified Party shall have the right to object, dissent, protest or
otherwise contest the same. The Seller Representative shall be able to rely
conclusively on the instructions and decisions of Buyer as to the settlement
of
any Claims for indemnification of the Buyer Indemnified Parties or any other
actions required to be taken by the Buyer Indemnified Parties
hereunder.
8.6 Seller
Representative.
(a) Appointment.
In
order to administer efficiently the requirements and provisions of this
Agreement including the defense and/or settlement of any Claims for which the
Buyer Indemnified Parties may be indemnified, the Sellers and the Indemnifying
Noteholder irrevocably appoint the Seller Representative as their agent,
attorney-in-fact and representative (with full power of substitution in the
premises), and, by its execution hereof, the Seller Representative hereby
accepts such appointment.
(b) Authorization.
The
Sellers and
the
Indemnifying Noteholder
hereby
authorize the Seller Representative (i) to take all action necessary in
connection with the defense and/or settlement of any Claims for which the Buyer
Indemnified Parties may be indemnified and (ii) to give and receive all notices
required to be given under this Agreement, the Escrow Agreement and the other
agreements contemplated hereby to which all of the Sellers and
the
Indemnifying Noteholder
or their
respective properties are subject.
30
(c) Replacement.
In the
event that the Seller Representative dies, becomes unable to perform his
responsibilities hereunder or resigns from such position, the remaining Sellers
shall, by election of the Sellers (or, if applicable, their respective heirs,
legal representatives, successors and assigns) who held a majority of the voting
power represented by the Securities issued and outstanding immediately prior
to
the Closing, select another representative to fill such vacancy and such
substituted representative shall be deemed to be the Seller Representative
for
all
purposes of this Agreement.
(d) Binding
Effect.
All
decisions and actions by the Seller Representative, including the defense or
settlement of any Claims for which the Buyer Indemnified Parties may be
indemnified, shall be binding upon all of the Sellers and the Indemnifying
Noteholder, and no Seller or the Indemnifying Noteholder has the right to
object, dissent, protest or otherwise contest the same. The Sellers and the
Indemnifying Noteholder agree that
(i) Buyer
shall be able to rely conclusively on the instructions and decisions of the
Seller Representative as to the settlement of any Claims for indemnification
of
the Buyer Indemnified Parties or any other actions required to be taken by
the
Seller Representative hereunder;
(ii) all
actions, decisions and instructions of the Seller Representative shall be
conclusive and binding upon all of the Sellers and
the
Indemnifying Noteholder
and no
Seller or the
Indemnifying Noteholder
shall
have any cause of action against the Seller Representative for any action taken
or not taken, decision made or instruction given by the Seller Representative
under this Agreement, except for fraud, gross negligence, willful misconduct
or
bad faith by
the
Seller Representative;
(iii) each
of
the Sellers and
the
Indemnifying Noteholder
shall
indemnify and hold harmless, pro rata based upon and up to an amount not to
exceed the respective amounts of Consideration Shares to which such Seller
or
the
Indemnifying Noteholder
is
entitled after satisfaction of any Claims, the Seller Representative from all
loss, liability or expense (including the reasonable fees and expenses of
counsel) arising out of or in connection with the Seller’s execution and
performance of this Agreement and the Escrow Agreement, except for fraud, gross
negligence, willful misconduct or bad faith by the Seller
Representative;
(iv) the
provisions of this Section
8.6
are
independent and severable, are irrevocable and coupled with an interest and
shall be enforceable notwithstanding any rights or remedies that any Seller
may
have in connection with the transactions contemplated by this Agreement;
and
(v) the
provisions of this Section
8.6
shall be
binding upon the heirs, legal representatives, successors and assigns of each
Seller and the Indemnifying Noteholder, and any references in this Agreement
to
a Seller or the Sellers or the Indemnifying Noteholder shall mean and include
the successors to the rights of the Sellers and the Indemnifying Noteholder,
hereunder, whether pursuant to testamentary disposition, the laws of
descent
and
distribution or otherwise
31
(e) Escrow
Agreement.
The
Seller Representative is authorized to enter into the Escrow Agreement on the
behalf of the Sellers which agreement may require the Sellers and the
Indemnifying Noteholder to indemnify the Escrow Agent for certain fees, expenses
and other liabilities.
8.7 Confidentiality.
The
Sellers acknowledge that the Intellectual Property and all other confidential
or
proprietary information with respect to the business and operations of the
Company are valuable, special and unique. Except as required by law or in
connection with the defense, dispute or resolution of a Claim involving the
Company, OPKO, Buyer or any other Buyer Indemnified Party, the Sellers shall
not, at any time after the Closing Date, disclose, directly or indirectly,
to
any Person, or use or purport to authorize any Person to use any Intellectual
Property, confidential or proprietary information with respect to the Company,
Buyer or OPKO, whether or not for a Seller’s own benefit, without the prior
written consent of Buyer, including without limitation, information as to the
financial condition, results of operations, customers, suppliers, products,
products under development, inventions, sources, leads or methods of obtaining
new products or business, Intellectual Property, pricing methods or formulas,
cost of supplies, marketing strategies or any other information relating to
the
Company or Buyer which could reasonably be regarded as confidential, but not
including information which is or shall become generally available to the public
other than as a result of an unauthorized disclosure by a Seller or a Person
to
whom a Seller has provided such information. The Sellers acknowledge that Buyer
would not enter into this Agreement without the assurance that all such
confidential and proprietary information will be used for the exclusive benefit
of the Company.
8.8 Dissolution.
If the
Company, Buyer or OPKO shall liquidate, dissolve or wind up or experience a
Triggering Event at any time before OPKO and Buyer shall have satisfied in
full
all of their respective obligations under this Agreement, whether fixed or
contingent (including, without limitation, the issuance and delivery and release
by the Escrow Agent of all of the
Note
Shares, the Note Indemnity Shares and the
Consideration Shares), Buyer shall notify the Seller Representative of the
same
as soon as possible under the circumstances and, in any event at least ten
days
before the consummation of the event giving rise to the notice.
8.9 Right
of First Offer.
The
Company hereby waives its rights under Section 4(c) of each of the restricted
stock purchase agreements between the Company and each Founder, dated as of
January 30, 2007, with respect to the right of first offer in favor of the
Company set forth therein, and consents to the sale of the Securities by the
Founders to Buyer on the terms set forth herein.
ARTICLE
9
Miscellaneous
9.1 Further
Assurances.
Each
party agrees (a) to furnish upon request to each other party such further
information, (b) to execute and deliver to each other party such other
documents, and (c) to do such other acts and things, all as another party
may reasonably request for the purpose of carrying out the intent of this
Agreement and the transactions contemplated by this Agreement.
32
9.2 Publicity.
The
parties agree to cooperate in issuing any press release or other public
announcement concerning this Agreement or the transactions contemplated hereby.
Nothing contained herein shall prevent any party from at any time furnishing
any
information to any governmental authority which it is by law or otherwise so
obligated to disclose or from making any disclosure which its counsel deems
necessary or advisable in order to fulfill such party’s disclosure obligations
under applicable Law or the rules of the SEC or AMEX.
9.3 Assignment of
Rights.
Each of
parties shall, without the payment of any additional consideration by any other
party, take all such actions as may be required to transfer all of his or its
right, title and interest in and to all assets, Intellectual Property,
contracts, agreements or other rights which are utilized by or for the benefit
of the Company in the conduct of their respective businesses so as to ensure
that all such rights, title and interest inure to the benefit of the
Company.
9.4 Notices.
Any
notice or other communication under this Agreement shall be in writing and
shall
be delivered personally or sent by certified mail, return receipt requested,
postage prepaid, or sent by facsimile or prepaid overnight courier to the
parties at the addresses set forth below their names on the signature pages
of
this Agreement (or at such other addresses as shall be specified by the parties
by like notice). Such notices, demands, claims and other communications shall
be
deemed given when actually received or (a) in the case of delivery by overnight
service with guaranteed next day delivery, the next day or the day designated
for delivery, (b) in the case of facsimile, the date upon which the transmitting
party received confirmation of receipt by facsimile, telephone or
otherwise.
9.5 Entire
Agreement.
This
Agreement, its schedules and exhibits, contain every obligation and
understanding between the parties relating to the subject matter hereof, merges
all prior discussions, negotiations and agreements, if any, between them, and
none of the parties shall be bound by any representations, warranties,
covenants, or other understandings, other than as expressly provided or referred
to herein or therein.
9.6 Assignment.
This
Agreement may not be assigned by any party without the written consent of the
other parties hereto; provided that Buyer may assign this Agreement to an
Affiliate, whether such Affiliate currently exists or is formed in the future;
and provided, further, that as a condition to and at the time of such
assignment, such Affiliate is solvent and OPKO shall Guaranty in writing Buyer’s
obligations under the Transaction Documents, and shall remain bound by its
obligations under the Transaction Documents in all respects. This Agreement
shall be binding upon and inure to the benefit of the parties hereto and their
respective successors, heirs, personal representatives, legal representatives,
and permitted assigns.
9.7 Waiver
and Amendment.
Any
representation, warranty, covenant, term or condition of this Agreement which
may legally be waived, may be waived, or the time of performance thereof
extended, at any time by the party hereto entitled to the benefit thereof,
and
any term, condition or covenant hereof may be amended by the parties hereto
at
any time. Any such waiver, extension or amendment shall be evidenced by an
instrument in writing executed on behalf of the appropriate party by a person
who, to the extent applicable, has been authorized by its Board of Directors
to
execute waivers, extensions or amendments on its behalf. No waiver by any party
hereto, whether express or implied, of its rights under any provision of this
Agreement shall constitute a waiver of such party’s rights under such provisions
at any other time or a waiver of such party’s rights under any other provision
of this Agreement. No failure by any party hereto to take any action against
any
breach of this Agreement or default by another party shall constitute a waiver
of the former party’s right to enforce any provision of this Agreement or to
take action against such breach or default or any subsequent breach or default
by such other party.
33
9.8 No
Third Party Beneficiary.
Nothing
expressed or implied in this Agreement is intended, or shall be construed,
to
confer upon or give any Person other than the parties hereto and their
respective heirs, personal representatives, legal representatives, successors
and permitted assigns, any rights or remedies under or by reason of this
Agreement.
9.9 Severability.
In the
event that any one or more of the provisions contained in this Agreement shall
be declared invalid, void or unenforceable, the remainder of the provisions
of
this Agreement shall remain in full force and effect, and such invalid, void
or
unenforceable provision shall be interpreted as closely as possible to the
manner in which it was written.
9.10 Disclosure
Generally.
Notwithstanding anything to the contrary contained in the Disclosure Schedules
or in this Agreement, the information and disclosures contained in any Schedule
of the Disclosure Schedules shall be deemed to be disclosed and incorporated
by
reference in any other Schedule of the Disclosure Schedules as though fully
set
forth in such Schedule for which applicability of such information and
disclosure is reasonably apparent on its face. The fact that any item of
information is disclosed in the Disclosure Schedules shall not be construed
to
mean that such information is required to be disclosed by this Agreement. Except
as expressly set forth in this Agreement, such information and the thresholds
(whether based on quantity, qualitative characterization, dollar amounts or
otherwise) set forth herein shall not be used as a basis for interpreting the
terms “material” or “Material Adverse Effect” or other similar terms in this
Agreement.
9.11 Expenses.
Each
party agrees to pay, without right of reimbursement from any other party, the
costs (hereafter referred to as “Costs”)
incurred by it incident to the performance of its obligations under this
Agreement and the consummation of the transactions contemplated hereby,
including, without limitation, costs incident to the preparation of this
Agreement, and the fees and disbursements of counsel, accountants and
consultants employed by such party in connection herewith.
9.12 Headings.
The
section and other headings contained in this Agreement are for reference
purposes only and shall not affect the meaning or interpretation of any
provisions of this Agreement.
9.13 Counterparts.
This
Agreement may be executed in any number of counterparts, each of which shall
be
deemed an original but all of which together shall constitute one and the same
instrument.
34
9.14 Injunctive
Relief.
It is
possible that remedies at law may be inadequate and, therefore, the parties
hereto shall be entitled to equitable relief including, without limitation,
injunctive relief, specific performance or other equitable remedies in addition
to all other remedies provided hereunder or available to the parties hereto
at
law or in equity.
9.15 Time.
Time is
of the essence with regard to all dates and time periods set forth or referred
to in this Agreement.
9.16 Governing
Law.
This
Agreement has been entered into and shall be construed and enforced in
accordance with the laws of the State of New York without
reference to the choice of law principles thereof.
35
IN
WITNESS WHEREOF, the parties hereto have each executed and delivered this
Agreement as of the day and year first above written.
OPKO
HEALTH, INC.
By:_________________________________
Name:
Title:
4400
Biscayne Boulevard, Suite 1180
Miami,
Florida 33137
Attn:
Kate Inman, Deputy General Counsel
OPKO
INSTRUMENTATION, LLC
By:_________________________________
Name:
Title:
4400
Biscayne Boulevard, Suite 1180
Miami,
Florida 33137
Attn:
Kate Inman, Deputy General Counsel
VIDUS
OCULAR, INC.
By:_________________________________
Name:
Title:
36
Sellers
and Noteholders:
__________________________________
J.
Anderson Berly, III
__________________________________
Ben
R. Bronstein
BEN
R. BRONSTEIN LIVING TRUST DA 03/04/96
By:___________________________
Name:
Title:
_________________________________
Joseph
M. Davie
JM
MEDICAL, LLC
By:___________________________
Name:
Title:
37
_________________________________
Robert
E. Mason III
_________________________________
James
R. McNab, Jr.
JAMES
R. AND MARY W.
MCNAB
OPERATING L.P.
By:______________________________
Name:
Title:
_________________________________
Milton
Bruce Shields
_________________________________
Nicholas
Fish Warner
_________________________________
Jay
Williams
_________________________________
Jennifer
Williams
YALE
UNIVERSITY
By:___________________________
Name:
Title:
38
SCHEDULE
A
Sellers
Seller
|
Securities
Owned
(Shares
of
Company
Common
Stock)
|
Yale
Shares
|
***
Shares
|
***
Shares
|
True-Up
Shares
|
Ben
R. Bronstein
|
***
|
***
|
***
|
***
|
***
|
James
R. McNab, Jr.
|
***
|
***
|
***
|
***
|
***
|
Milton
Bruce Shields
|
***
|
***
|
***
|
***
|
***
|
Nicholas
Fish Warner
|
***
|
***
|
***
|
***
|
***
|
Yale
University
|
***
|
***
|
***
|
***
|
***
|
Total
|
3,710,769
|
33,080
|
227,670
|
260,750
|
413,850
|
*Other
Schedules are omitted as permitted in accordance with Item 601 of Regulation
S-K.
i